A phase II clinical trial on the efficacy and safety of carboplatin plus nab-paclitaxel in chemotherapy-naive advanced or recurrent thymic epithelial tumors: protocol of Nab-TET.

ABSTRACT:

Background

Thymic epithelial tumors (TETs) are rare, posing challenges for conducting large-scale clinical trials and leading to slower therapeutic advancements compared with other cancers. Although carboplatin plus paclitaxel therapy is the preferred standard treatment, its clinical use presents challenges, including the frequent occurrence of peripheral neuropathy. In a phase III study, carboplatin plus nab-paclitaxel therapy demonstrated superior efficacy over carboplatin plus paclitaxel therapy in advanced or recurrent non-small cell lung cancer, with reduced adverse events such as peripheral neuropathy, neutropenia, and myalgia. Carboplatin plus nab-paclitaxel therapy has the potential to offer similar efficacy with reduced toxicity in TETs. Therefore, we plan to conduct a pha

SUBMITTER: Hayashi F 

PROVIDER: S-EPMC12557666 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature